No abstract available.
Gestational Age* ; Mortality

PURPOSE: We investigated whether in utero exposure to magnesium sulfate is associated with lower incidence of neonatal mortality, morbidity, and neurodevelopmental abnormalities in very low birth weight infants. METHODS: We evaluated 172 infants with birth weight less than 1,500g. According to the maternal receipt of magnesium sulfate, we divided into two groups. We reviewed the medical records of mothers and their babies to evaluate clinical outcome. RESULTS: Of 172 infants, 58(GA 30.0+/-2.3weeks, BW 1,20+/-2221g) received magnesium sulfate prior to delivery for tocolysis or preeclampsia(study group). The remaining 114(GA 29.6+/-2.3weeks, BW 1,220 +/-198g) served as the control group. Neonatal mortality was not significantly different between the two groups(12.5% vs 26.0%). There was no significant difference between the two groups in neonatal complications' RDS(52.4% vs 67.6%), BPD(16.7% vs 29.6%), apnea(52.4% vs 67.6%), IVH(23.8% vs 31.0%), PVL(4.8% vs 11.3%), NEC(7.1% vs 7.0%), ROP(26.8% vs 41.2%), and neal infection(33.3% vs 54.9%). The duration of ventilator therapy(10.9+/-7.3 vs 14.2+/-10.6 days), oxygen administration(20.2+/-20.0 vs 24.3+/-19.9 days) and admission(51.5+/-16.9 vs 54.6+/-16.7 days) were not different. Among 64 patients in whom follow up evaluation was possible more than 1 year, the incidence of cerebral palsy or developmental delay was not different(12.0% vs 12.8%). CONCLUSION: Maternal receipt of magnesium sulfate does not seem to be associated with an appreciably reduced risk of neonatal mortality, morbidity, and neurodevelopmental abnormalities in very low birth weight infants. (Abbreviations. GA, gestational age, BW, birth weight; RDS, respiratory distress syndrome; BPD, bronchopulmonary dysplasia, IVH, intraventricular hemorrhage; PVL, periventricular leukomalacia; NEC, necrotizing enterocolitis; ROP, retinopathy of prematurity)
Birth Weight ; Bronchopulmonary Dysplasia ; Cerebral Palsy ; Enterocolitis, Necrotizing ; Follow-Up Studies ; Gestational Age ; Hemorrhage ; Humans ; Incidence ; Infant ; Infant Mortality* ; Infant* ; Infant, Newborn ; Infant, Very Low Birth Weight* ; Leukomalacia, Periventricular ; Magnesium Sulfate* ; Magnesium* ; Medical Records ; Mothers ; Oxygen ; Tocolysis ; Ventilators, Mechanical

No abstract available.
Lipodystrophy*

No abstract available.
Vitamin K* ; Vitamins*

PURPOSE: The purpose of this study was to identify the conceptual structure of stressors experienced by nursing students during clinical practice. METHODS: Ten men and 10 women nursing college students were interviewed. The results were 208 ideas. By synthesizing and editing these ideas, the final statement was trimmed down to 39 questions. The next step was to have the participants classify these 39 final questions. They were asked to rate stress scores using a five-point scale. Through multidimensional scaling analysis and hierarchical cluster analysis yielded dimensions and clusters. RESULTS: Results of the study showed 2 dimensions which were classified as 'interpersonal relationship-practice system' and 'identity-practice environment'. It also yielded 8 clusters which were classified as 'role confusion', 'gender discrimination', 'attitudes of medical personnel and patients', 'comparison between fellow students', 'difference between theory and practice', 'disestablishing the role of practice guide', 'interference with training', and 'problems of the practice environment'. Further, stress factors and stress levels were differentiated depending on the gender of the student. CONCLUSION: The results of the study indicate that educators who are developing clinical practice programs and clinical practitioners should consider stressors during clinical practice and the educational implications to nursing students.
Female ; Humans ; Male ; Nursing ; Students, Nursing*

No abstract available.

BACKGROUND: Currently, the incidence of hepatitis A is on the increase in Korea. Although there is emphasis on contact precautions, the nosocomial outbreak of hepatitis A virus (HAV) in healthcare personnel has increased within endemic areas because these workers inevitably come in close contact with patients and work under suboptimal hygiene conditions. In this study, we evaluated the necessity of immunization against HAV for healthcare personnel. METHODS: We investigated the seropositivity of serum immunoglobulin G (IgG) anti-HAV antibody (Ab) in 672 healthcare personnel on the basis of their age-group, sex, and occupation in Soon Chun Hyang University Hospital and Soon Chun Hyang University Bucheon Hospital. RESULTS: The subjects were divided into 6 groups on the basis of their ages to identify differences among the various age groups in the number of cases with HAV Ab seropositivity. Significant intergroup differences were noted in this respect: 21-25 years, 2/152 (1.3%); 26-30 years, 33/245 (13.5%); 31-35 years, 70/148 (47.3%); 36-40 years, 52/79 (65.8%); >40 years, 44/48 (91.7%). CONCLUSION: The number of seropositive cases was low among young healthy personnel: low seropositivity is an emerging risk for vulnerable population. With the increase in the incidence of hepatitis A, healthcare personnel have become a risk population for hepatitis A, as are community residents. Therefore, for healthcare personnel working in hospitals, immunization against HAV should be recommended for personnel younger than 30 years, and serological testing for older personnel.
Delivery of Health Care ; Hepatitis ; Hepatitis A ; Hepatitis A Antibodies ; Hepatitis A Vaccines ; Hepatitis A virus ; Humans ; Hygiene ; Immunization ; Immunoglobulin G ; Incidence ; Korea ; Occupations ; Serologic Tests ; Vulnerable Populations

PURPOSE: The objective of this work is to determine whether the degree of expression of Human Erythrocyte Glucose Transporter (Glut-1) protein might correlate with survival rate, tumor stage and pathologic findings in renal cell carcinoma (RCC). MATERIALS AND METHODS: 94 patients who underwent radical nephrectomy at our department for RCC were included in this retrospective study. Biologic significance of Glut-1 immunohistochemical staining according to the survival rate, tumor stage and pathologic findings in patients with RCC was evaluated. Immunohistochemical staining was performed using a primary antibody which was polyclonal rabbit anti-human Glut-1. RESULTS: In 67 of 94 patients, Glut-1 staining was demonstrated in the plasma membrane of cancer cells. Positive staining of Glut-1 in clear cell type was significantly higher than chromophobe type and chromophill type (p=0.01, 0.04). Positive staining for Glut-1 did not show any significant difference between localized and metastatic RCC. Positive staining for Glut-1 did not show any significant difference with tumor stage (p=0.09) or nuclear grade (p=0.20) or survival rate in localized RCC. CONCLUSIONS: In summary, Glut-1 protein express not in the normal portion of kidney but in the RCC. Expression of Glut-1 protein does not correlate with tumor stage, nuclear grade, or survival rate. These findings suggest that RCC may have another type of glucose transporter.
Carcinoma, Renal Cell* ; Cell Membrane ; Erythrocytes* ; Glucose Transport Proteins, Facilitative ; Glucose Transporter Type 1* ; Humans* ; Immunohistochemistry ; Kidney ; Nephrectomy ; Prognosis ; Retrospective Studies ; Survival Rate

BACKGROUND/AIMS: Entecavir is a synthetic nucleoside analogue, cyclopentyl guanine nucleoside, which has a potent antiviral effect and the least viral breakthrough in hepatitis B virus (HBV) replication. Entecavir has been available in Korea since 2007 but there are few reports on its effects. The aim of this study was to evaluate the virological response (VR) and biochemical response (BR) to entecavir in HBV patients at 3, 6 and 9 months after treatment with entecavir. MATERIALS AND METHODS: Thirty-three chronic hepatitis B patients who took entecavir for at least 9 months were enrolled. We investigated VR and BR by retrospectively reviewing medical records. Patients who satisfied the following criteria were chosen: 1) initial alanine aminotransferase (ALT) levels = 1.5upper limit of normal (ULN) and 2) initial HBV DNA levels = 5 log10 copies/ml. We measured ALT levels every 3 months until month 9. HBV DNA was measured every 2 or 3 months by polymerase chain reaction (PCR) method. RESULTS: Most patients taking entecavir showed good BR (ALT < 40 IU/L). The BR rates were 61%, 73% and 67% at months 3, 6 and 9, respectively. VR (HBV DNA < 5 log(10) copies/ml or 2 log lower than initial HBV DNA) rates were 82%, 91% and 91% at months 3, 6 and 9, respectively. Undetectable HBV DNA (HBV DNA < 4 log(10) copies/ml) rates were 49%, 73% and 85% at months 3, 6 and 9, respectively. Two patients presented with virological breakthrough without adverse effects until month 9. CONCLUSIONS: Entecavir showed good BR and VR from month 3 and these effects continued through the 9-month observation period. This suggests that entecavir is also a good choice for the first line treatment of chronic hepatitis B (CHB). Further studies are needed to determine the long-term efficacy and drug resistance of entecavir in Korean CHB patients.
Alanine Transaminase ; DNA ; Drug Resistance ; Guanine ; Hepatitis B virus ; Hepatitis B, Chronic ; Hepatitis, Chronic ; Humans ; Korea ; Medical Records ; Polymerase Chain Reaction ; Retrospective Studies

No abstract available.
Acinetobacter Infections* ; Acinetobacter* ; Infant, Newborn ; Intensive Care, Neonatal*